Compare Merck & Co., Inc. (MRK) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while ProShares UltraPro Short QQQ ETF trades at $39.1. The key difference: Merck & Co., Inc. pays a 2.3% dividend while ProShares UltraPro Short QQQ ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SQQQ | |
|---|---|---|
Market Cap | $363.98B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $89.43 |
52-Week Low | $77.60 | $36.04 |
Enterprise Value | $410.75B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $38.31, up 0.34% on the day. Technical indicators are bearish with moving averages signaling sell, while oscillators remain neutral. The ETF is designed for short-term hedging against tech declines but faces structural erosion from daily resets, as highlighted by Seeking Alpha on 2026-06-26. Recent news suggests tactical use amid AI-driven market volatility, but long-term holding risks severe losses.
Outlook: SQQQ offers tactical downside protection in bearish tech markets but is unsuitable for long-term investment due to leverage decay. Risks include rapid value erosion and high volatility, requiring precise timing. Opportunities exist for hedging QQQ exposure during corrections, but investors must monitor Nasdaq-100 trends closely to avoid capital depletion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
